**S3 Table. BZD prescribing patterns by average daily dosage in 117,739 study participants during the study period (2006-2013)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Covariate** | **Total *n*a** |  | **Average daily dosage** | | | | | | | | |
|  | **˂0.5 DDD (reference)** |  | **≥0.5DDD to <1.5DDD** | | |  | **≥1.5DDD** | | |
|  |  | ***n* (%)** |  | ***n* (%)** | **Crude**  **OR (95% CI)** | **Adjustedb**  **OR (95% CI)** |  | ***n* (%)** | **Crude**  **OR (95% CI)** | **Adjustedb**  **OR (95% CI)** |
| **Whole cohort** | 117,739 |  | 98,852 (83.96) |  | 15,885 (13.49) |  |  |  | 3,002 (2.55) |  |  |
| **Sex** |  |  |  |  |  |  |  |  |  |  |  |
| Females | 67,313 |  | 57,219 (85.00) |  | 8,697 (12.92) | 1.00 | 1.00 |  | 1,397 (2.08) | 1.00 | 1.00 |
| Males | 50,426 |  | 41,633 (82.56) |  | 7,188 (14.25) | 1.14 (1.10-1.17) | 1.29 (1.25-1.34) |  | 1,605 (3.18) | 1.58 (1.47-1.70) | 1.81 (1.69-1.95) |
| **Age at first BZD dispensation** |  |  |  |  |  |  |  |  |  |  |  |
| 0-11 years | 17,500 |  | 16,850 (96.29) |  | 607 (3.47) | 1.00 | 1.00 |  | 43 (0.25) | 1.00 | 1.00 |
| 12-17 years | 15,039 |  | 12,618 (83.90) |  | 2,069 (13.76) | 4.55 (4.15-5.00) | 2.34 (2.12-2.59) |  | 352 (2.34) | 10.93 (7.96-15.02) | 5.90 (4.26-8.17) |
| 18-24 years | 85,200 |  | 69,384 (81.44) |  | 13,209 (15.50) | 5.28 (4.86-5.74) | 2.77 (2.51-3.05) |  | 2,607 (3.06) | 14.72 (10.89-19.91) | 8.90 (6.47-12.23) |
| **Any lifetime psychiatric diagnosisc** | 68,476 |  | 52,308 (76.39) |  | 13,381 (19.54) | 4.75 (4.54-4.97) | 3.05 (2.91-3.20) |  | 2,787 (4.07) | 11.53 (10.03-13.26) | 7.00 (6.08-8.06) |
| **Lifetime diagnosis of epilepsyd** | 15,191 |  | 13,213 (86.98) |  | 1,635 (10.76) | 0.74 (0.70-0.79) | 1.01 (0.94-1.07) |  | 343 (2.26) | 0.84 (0.75-0.94) | 1.45 (1.27-1.64) |
| **Concurrent dispensation of any psychotropic medicatione** | 89,400 |  | 71,404 (79.87) |  | 15,088 (16.88) | 7.28 (6.77-7.82) | 3.99 (3.69-4.30) |  | 2,908 (3.25) | 11.89 (9.68-14.61) | 4.88 (3.96-6.02) |

aTotal number of individuals in each row represents 100%.

bAdjusted for all variables in the table.

cReference category is the individuals without any lifetime psychiatric diagnosis.

dReference category is the individuals without lifetime epilepsy.

eReference category is the individuals without any concurrent psychotropic medication, i.e., psychotropic medication dispensed within 6 months prior to or after BZD dispensation.

BZD, benzodiazepine or benzodiazepine-related drug; OR, odds ratio.